09:50 AM EST - Oncolytics Biotech Inc. : announced today that the Company's independent Data Monitoring Committee (DMC) has reviewed the safety data for the first stage of its Phase III trial of REOLYSIN in combination with carboplatin and paclitaxel for the treatment of head and neck cancers. Oncolytics Biotech Inc.
shares T.ONC are trading up $0.06 at $3.42.
